Influence of isoprostanes on vasoconstrictor effects of noradrenaline and angiotensin II

European Journal of Pharmacology

Volumn 378, Issue 1, 1999, Pages 47-55

  Sametz, Wolfgang ^a   Grobuschek, Tanja ^a   Hammer Kogler, Susanne ^a   Juan, Heinz ^a   Wintersteiger, Reinhold ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Angiotensin II; Isoprostane; Noradrenaline; Prostaglandin; U 46619; Vasoconstriction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN; ISOPROSTANE DERIVATIVE; NORADRENALIN; PROSTAGLANDIN E1; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F3 ALPHA;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG POTENTIATION; EAR; FEMALE; ISOLATED ORGAN; MALE; NONHUMAN; ORGAN PERFUSION; PRIORITY JOURNAL; RABBIT; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANGIOTENSIN II; ANIMALS; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EAR; F2-ISOPROSTANES; FEMALE; HYDRAZINES; MALE; NOREPINEPHRINE; PERFUSION; PROSTAGLANDINS; RABBITS; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0032780427     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00437-9     Document Type: Article

References (41)

1. Andersen, N.H., Ramwell, P.W., Leovey, E.M.K., Johnson, M., 1976. Biological consequences of prostaglandin molecular conformations. In: Samuelsson, B., Paoletti, R. (Eds.), Advances in Prostaglandin and Thromboxane Research, Vol. 1. Raven Press, New York, NY, pp. 271-289.
2. Ariëns E.J., van Rossum J.M., Simonis A.M. A theoretical basis of molecular pharmacology: I. Interactions of one or two compounds with one receptor system. Arzneim.-Forsch. 6:1956;282-293.
3. Burton, A.C., 1965. Physiology and Biophysics of the Circulation. Year Book Medical Publisher, Chicago, IL.
4. 2 alpha is increased in hypercholesterolemia. Arterial Thromboembolism Vasc. Biol. 17:1997;3230-3235.
5. 2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation. 95:1997;2492-2499.
6. 1: New Aspects on Pharmacology, Metabolism and Clinical Efficacy. Springer-Verlag, Berlin.
7. Drevon, C.A., Baksaas, I., Krokan, H.E., 1993. Omega-3 Fatty Acids: Metabolism and Biological Effects. Birkhäuser Verlag, Basel.
8. Halliwell B., Grootveld M. The measurement of free radical reactions in humans. FEBS Lett. 213:1987;9-14.
9. Juan H., Lembeck F. Release of prostaglandins from the isolated perfused rabbit ear by bradykinin and acetylcholine. Agents and Actions. 6:1976;642-645.
10. Juan H., Sametz W. Histamine-induced release of arachidonic acid and prostaglandins in the peripheral vascular bed. Naunyn-Schmiedeberg's Arch. Pharmacol. 314:1980;183-190.
11. Juan H., Sametz W. Vasoconstriction induced by noradrenaline and angiotensin II is antagonized by eicosapentaenoic acid independent of formation of trienoic eicosanoids. Naunyn-Schmiedeberg's Arch. Pharmacol. 332:1986;288-292.
12. Juan H., Sametz W., Saria A., Pöch G. Eicosapentaenoic acid inhibits vasoconstrictor- and noradrenaline-potentiating effects of neuropeptide Y in the isolated rabbit ear. J. Auton. Nerv. Syst. 22:1988;237-242.
13. Kernoff P.B., Willis A.L., Stone K.J., Davies J.A., McNicol G.P. Antithrombotic potential of dihomo-gamma-linolenic acid in man. Br. Med. J. 2:1977;1441-1444.
14. Kopin, I.J., 1989. Plasma levels of catecholamines and dopamine-β-hydroxylase. In: Trendelenburg, U., Weiner, R. (Eds.), Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, pp. 212-275.
15. 2α. Br. J. Pharmacol. 119:1996;1276-1280.
16. 2 alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 16:1998;1536-1539.
17. Mancini G.B. Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease. Cardiovasc. Drugs Ther. 10(2):1996;609-612. Suppl.
18. 2) in isolated guinea pig hearts. J. Cardiovasc. Pharmacol. 29:1997;789-794.
19. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1997;1-21.
20. Morrow J.D., Harris T.M., Roberts L.J. II Non-cyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184:1990;1-10.
21. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9383-9387.
22. 2α, is formed in vivo. Biochem. Biophys. Acta. 1210:1994;244-248.
23. Morrow J.D., Minton T.A., Mukundan C.R., Campbell M.D., Zackert W.E., Daniel V.C., Badr K.F., Blair I.A., Roberts L.J. II Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 269:1994;4317-4326.
24. 2-isoprostanes in vitro and in vivo - effects of oxygen tension and glutathione. Arch. Biochem. Biophys. 353(1997):1997;160-171.
25. 2) is formed in vivo. J. Lipid Res. 39:1998;1589-1593.
26. Nicosia S., Patrono C. Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. FASEB J. 3:1989;1941-1948.
27. Nourooz-Zadeh J., Halliwell B., Anggard E.E. Evidence for formation of F-3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 236:1989;467-472.
28. Pöch G., Holzmann S. Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves. J. Pharmacol. Methods. 4:1980;179-188.
29. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
30. Riegger G.A. Role of renin-angiotensin system as a risk factor for control of morbidity and mortality in coronary artery disease. Cardiovasc. Drugs Ther. 10(2):1996;613-615. Suppl.
31. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Dettbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
32. Ross R. The pathogenesis of atherosclerosis - an update. New Engl. J. Med. 314:1986;488-500.
33. Sametz W., Prasthofer S., Krobuschek T., Wintersteiger R., Juan H. Vascular effects of isoprostanes. Naunyn-Schmiedeberg's Arch. Pharmacol. 356(1):1997;R7. Suppl.
34. 3α. Naunyn-Schmiedeberg's Arch. Pharmacol. 358(2):1998;R718. Suppl.
35. Schömig A., Haess M., Richardt G. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur. Heart J. 12:1991;38-47.
36. Schwandt, P., 1991. Effects of Omega-3 Fatty Acids. Schattauer, Stuttgart.
37. Shaw, A.M., McGrath, J.C., 1996. Initiation of smooth muscle response. In: Garland, C.J., Angus, J.A. (Eds.), Pharmacology of Vascular Smooth Muscle. Oxford Univ. Press, Oxford, pp. 103-135.
38. 1 in Atherosclerosis. Springer-Verlag, Berlin.
39. 1 on vasoconstriction induced by noradrenaline and 5-HT in rat mesenteric vasculature. Prostaglandin Leukotriene Essent. Fatty Acids. 33:1988;7-12.
40. Szczeklik A., Gryglewski R.J., Sladek K., Kostka-Trabka E., Zmuda A. Dihomo-gamma-linolenic acid in patients with atherosclerosis: effects on platelet aggregation, plasma lipids and low density lipoprotein-induced inhibition of prostacyclin generation. Thromb. Haemostasis. 51:1984;186-188.
41. 2α in the rat. J. Clin. Invest. 90:1992;136-141.